Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors

British Journal of Pharmacology

Volumn 147, Issue 4, 2006, Pages 360-370

  Olianas, Maria C ^a   Concas, Danilo ^a   Onali, Pierluigi ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

35S GTP S binding; Cyclic AMP; Naloxone benzoylhydrazone; Rat striatum; Receptor binding; Recombinant human opioid receptors

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ADENYLATE CYCLASE; CYCLIC AMP; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE BENZOYLHYDRAZONE; NALTRINDOLE; NOCICEPTIN RECEPTOR; NORBINALTORPHIMINE; OPIATE RECEPTOR; RECOMBINANT RECEPTOR; SULFUR 35;

AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; STIMULATION;

ADENYLATE CYCLASE; ANIMALS; BINDING, COMPETITIVE; CELL CULTURE TECHNIQUES; CELL EXTRACTS; CELL MEMBRANE; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; RECOMBINANT PROTEINS; SULFUR RADIOISOTOPES;

EID: 33644559085     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706601     Document Type: Article

References (49)

1. 2+ channel current in rat sensory neurons by a G-protein- independent mechanism. J. Neurosci., 17, 8721-8728.
2. BERZETEI-GURSKE, I.P., WHITE, A., POLGAR, W., DeCOSTA, B.R., PASTERNAK, G.W. & TOLL, L. (1995). The in vitro pharmacological characterization of naloxone benzoylhydrazone. Eur. J. Pharmacol., 277, 257-263.
3. BIGONI, R., CAO, G., RIZZI, A., OKAWA, H., REGOLI, D., SMART, D. & LAMBERT, D.G. (2002). Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors. Can. J. Physiol. Pharmacol., 80, 407-412.
4. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem, 72, 248-254.
5. 3H-Naloxone benzoylhydrazone binding in MOR-1-transfected chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding. J. Pharmacol. Exp. Ther., 286, 376-381.
6. CALO', G., BIGONI, R., RIZZI, A., GUERRINI, R., SALVADORI, S. & REGOLI, D. (2000). Nociceptin/orphaninFQ receptor ligands. Peptides, 21, 935-947.
7. 3-Opiate receptor binding in the mouse and rat. Eur. J. Pharmacol. Mol. Pharmacol. Sect., 226, 15-20.
8. 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line. J. Neurochem., 65, 170-175.
9. i) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3102.
10. + channels by nociceptin and a μ-opioid in rat periaqueductal grey slices. Naunyn-Schmiedeberg's Arch. Pharmacol., 363, 583-589.
11. CISZEWSKA, G.R., GINOS, J.A., CHARTON, M., STANDIFER, K.M., BROOKS, A.I., BROWN, G.P., RYAN-MORO, J.P., BERZETEI-GURSKE, I., TOLL, L. & PASTERNAK, G.W. (1996). Synthesis and characterization of substituted benzoylhydrazones of naloxone. Synapse, 24, 193-201.
12. 3 subtype. J. Pharmacol. Exp. Ther., 251, 461-468.
13. COX, V., CLARKE, S., CZYZYK, T., ANSONOFF, M., NITSCHE, J., HSU, M.-S., BORSODI, A., TOMBOLY, C., TOTH, G., HILL, R., PINTAR, J. & KITCHEN, I. (2005). Autoradiography in opioid triple knock-out mice reveals opioid and opioid receptor like binding of naloxone benzoylhydrazone. Neuropharmacology, 48, 228-235.
14. DARLAND, T., HEINRICHER, M.M. & GRANDY, D.K. (1998). Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Pharmacol. Sci., 21, 215-221.
15. DUNNILL, R.J., KAKIZAWA, K., McKNIGHT, A.T. & HENDERSON, G. (1996). Characterization of the actions of naloxone benzoylhydrazone at μ-opioid, κ-opioid and ORL1 receptors in isolated tissues from rat and guinea pig. Br. J. Pharmacol., 119, 275P.
16. EHLERT, F.J. (1985). The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol., 28, 410-421.
17. 6 glioma cell line expressing the μ opioid receptor. J. Pharmacol. Exp. Ther., 278, 1121-1127.
18. FLAU, K., REDMER, A., LIEDTKE, S., KATHMANN, M. & SCHLICKER, E. (2002). Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors. Br. J. Pharmacol., 137, 1355-1361.
19. FLEMING, W.W., WESTFALL, D.P., DE LA LANDE, S. & JELLET, L.B. (1972). Log-normal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J. Pharmacol. Exp. Ther., 181, 339-345.
20. FRANCE, C.P. & WOODS, J.H. (1992). Naloxone benzylhydrazone is a μ-selective opioid antagonist without kappa agonist effects in rhesus monkeys. Behav. Pharmacol., 3, 133-141.
21. GISTRAK, M.A., PAUL, D., HAHN, E.F. & PASTERNAK, G.W. (1989). Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone. J. Pharmacol. Exp. Ther., 251, 469-476.
22. GUTSTEIN, H.B. & AKIL, H. (2001). Opioid analgesics. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, ed. Hardman, J.G., Limbird, L.E. & Goodman Gilman, A. pp. 569-619. New York: McGraw-Hill Book Company.
23. HARRISON, L.M., KASTIN, A.J. & ZADINA, J.E. (1998). Differential effects of endomorphin-1, endomorphin-2, and Tyr-W-MIF-1 on activation of G proteins in SH-SY5Y human neuroblastoma membranes. Peptides, 19, 749-753.
24. HAWKINSON, J.E., ACOSTA-BURRUEL, M. & ESPITIA, S.A. (2000). Opioid activity profiles indicate similarities between the nociceptin/ orphanin FQ and opioid receptors. Eur. J. Pharmacol., 389, 107-114.
25. HOSOHATA, K., BURKEY, T.H., ALFARO-LOPEZ, J., VARGA, E., HRUBY, V.J., ROESKE, W.R. & YAMAMURA, H.Y. (1998). Endomorphin-1 and endomorphin-2 are partial agonists at the human μ-opioid receptor. Eur. J. Pharmacol., 346, 111-114.
26. MANSOUR, A., FOX, C.A., AKIL, H. & WATSON, S.J. (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci., 18, 22-29.
27. MATHIS, J.P., MANDYAM, C.D., ALTEMEMI, G.F., PASTERNAK, G.W. & STANDIFER, K.M. (2001). Orphanin FQ/nociceptin and naloxone benzoylhydrazone activate distinct receptors in BE(2)-C human neuroblastoma cells. Neurosci. Lett., 299, 173-176.
28. McDONALD, J., BARNES, T.A., OKAWA, H., WILLIAMS, J., CALO', G., ROWBOTHAM, D.J. & LAMBERT, D.G. (2003). Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ectysone-inducible mammalian expression system. Br. J. Pharmacol., 140, 61-70.
29. MEUNIER, J.C. (2000). The potential therapeutic value of nociceptin receptor agonists and antagonists. Exp. Opin. Ther. Patents, 10, 371-388.
30. MEUNIER, J.C., MOLLERAU, C., TOLL, L., SUAUDEAU, C., MOISAND, C., ALVINERIE, P., BUTOUR, J.L., GUILLEMOT, J.C., FERRARA, P., MONSERRAT, B., MAZARGUIL, H., VASSART, G., PARMENTIER, M. & COSTENTIN, J. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 377, 532-535.
31. MINOWA, S., ISHIHARA, S., TSUCHIYA, S., HORIE, S., WATANABE, K. & MURAYAMA, T. (2003). Involvement of glutamate and gamma-amino-butyric acid receptor systems on gastric acid secretion induced by activation of kappa-opioid receptors in the central nervous system in rats. Br. J. Pharmacol., 138, 1049-1058.
32. MOGIL, J.S. & PASTERNAK, G.W. (2001). The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev., 53, 381-415.
33. MUNSON, P.J. & RODBARD, D. (1980). Ligand: a versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem., 107, 220-239.
34. NABESHIMA, T., NODA, Y. & MAMIYA, T. (1999). The role of nociceptin in cognition. Brain. Res., 848, 167-173.
35. NODA, Y., MAMIYA, T., NABESHIMA, T., NISHI, M., HIGASHIOKA, M. & TAKESHIMA, H. (1998). Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice. J. Biol. Chem., 273, 18047-18051.
36. ONALI, P. & OLIANAS, M.C. (2004). G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb. Br. J. Pharmacol., 143, 638-648.
37. 3-related opioid receptor. Mol. Pharmacol., 47, 1180-1188.
38. PAN, Y.-X., XU, J., RYAN-MORO, J., MATHIS, J., HOM, J.S.H., MEI, J. & PASTERNAK, G.W. (1996). Dissociation of affinity and efficacy in KOR-3 chimeras. FEBS Lett., 395, 207-210.
39. PAUL, D., LEVISON, J.A., HOWARD, D.H., PICK, C.G., HAHN, E.F. & PASTERNAK, G.W. (1990). Naloxone benzoylhydrazone (NalBzoH) analgesia. J. Pharmacol. Exp. Ther., 255, 769-774.
40. PELTON, J.T., KAZMIERSKI, W., GULYA, K., YAMAMURA, H.I. & HRUBY, V.J. (1986). Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for μ opioid receptors. J. Med. Chem., 29, 2370-2375.
41. PICK, C.G., PETER Y SCHREIBER, S. & WEIZMAN, R. (1997). Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res., 744, 41-46.
42. 3H]naloxone benzoylhydrazone: a reversible κ and slowly dissociable μ opiate. Mol. Pharmacol., 35, 67-74.
43. REINSCHEID, R.K., NOTHACKER, H.P., BOURSON, A., ARDATI, A., HENNINGSEN, R.A., BUNZOW, J.R., GRANDY, D.K., LANGEN, H., MOSMA, F.J. & CIVELLI, O. (1995). Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science, 270, 792-794.
44. REISINE, T. & PASTERNAK, G.W. (1996). Opioid analgesics and antagonists. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, ed. Hardman, J.G., Limbird, L.E. & Goodman Gilman, A. pp. 521-555. New York: McGraw-Hill Book Company.
45. SALOMON, Y., LONDOS, D. & RODBELL, M. (1974). A highly sensitive adenylate cyclase assay. Anal. Biochem., 58, 541-548.
46. SEKI, T., AWAMURA, S., KIMURA, C., IDE, S., SAKANO, K., MINAMI, M., NAGASE, H. & SATOH, M. (1999). Pharmacological properties of TRK-820 on cloned μ-, δ-, and κ-opioid receptors and nociceptin receptor. Eur. J. Pharmacol., 376, 159-167.
47. 35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther, 285, 496-505.
48. 3 opioid receptors expressed in BE(2)-C neuroblastoma cells. J. Pharmacol. Exp. Ther., 270, 1246-1255.
49. STANDIFER, K.M., MURTHY, L.R., KINOUCHI, K., STEELE, L. & PASTERNAK, G.W. (1991). Affinity labeling of μ and κ receptors with naloxone benzoylhydrazone. Mol. Pharmacol., 39, 290-298.